MHRA - Updated Statement On The Outcome of The Brexit Referendum
On 15th of July 2016, MHRA has updated their statement on Brexit Referendum
21st July 2016
The Agency's response to the outcome of the EU referendum:
Following the EU referendum, MHRA continues to play a full, active role in European regulatory procedures. We continue to contribute significantly in both the centralised and decentralised regulatory procedures, including new rapporteur and RMS appointments and to maintain the programme for implementing the clinical trial regulation. We are actively engaged in European and national scientific advice services. We continue to provide the full service that companies in the UK have come to expect from us. We also continue to participate fully in EU inspection related duties.
Customers approaching MHRA, whether for regulatory or scientific advice or guidance, or to submit an application for a clinical trial or marketing authorisation, will continue to have access to our internationally recognised expertise and we will maintain a high quality service. For further information, customers are invited to contact their usual contact points in the Agency.
Following the result of the referendum on the UK’s membership of the European Union, the focus of the Medicines and Healthcare products Regulatory Agency continues to be on our public health role. We will continue to work to the highest levels of excellence and quality, working with and supporting our customers, partners and stakeholders to protect health and improve lives.
Working closely with government we will consider the implications for the work of the Agency. We will continue to make a major contribution globally to improving public health through the effective regulation of medicines and medical devices, underpinned by science and research.